Dr Shervin Zandi, assistant clinical professor at the Department of Medicine, McMaster University, joins Dr Khalid Azzam during the Chair's Medical Grand Rounds to present a comprehensive review of the expanding role of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in the treatment of diabetes, heart failure, and chronic kidney disease, as well as to discuss special considerations and precautions associated with these agents. The webinar was recorded on October 14, 2021.
0:00
/
0:00
Loaded: 0%
0:00
Progress: 0%
Stream TypeLIVE
0:00
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
See also
SGLT-2 inhibitors: A quick guide
The quick guide to sodium-glucose cotransporter-2 (SGLT-2) inhibitors for glycemic control, renal protection, or cardiovascular protection developed at McMaster University.
(R)evolution of pharmacologic therapy for diabetes mellitus
Dr Ally Prebtani, professor of medicine in the Division of Endocrinology and Metabolism at McMaster University, discusses the recently published meta-analysis of the use of SGLT-2 inhibitors and GLP-1 receptor agonists in diabetes.
Heart failure treatment: SGLT-2 inhibitors
Dr Harriette Van Spall, associate professor in the Division of Cardiology at McMaster University, scientist at the Population Health Research Institute, and cardiologist at Hamilton Health Sciences, answers questions about the role of SGLT-2 inhibitors in heart failure treatment.
Diabetic ketoacidosis (DKA)
Diabetic ketoacidosis: all that you need to remember about presentation, diagnosis, and management reviewed in less than 10 minutes.
English
Polski
Español
українська
